- Home
- NERV vs CLPS Comparison
NERV vs CLPS Comparison
Compare NERV & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NERV | CLPS |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 25.8M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NERV | CLPS |
|---|---|---|
| Price | $3.97 | $0.87 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 40.4K | 10.4K |
| Earning Date | 11-05-2025 | 10-17-2025 |
| Dividend Yield | N/A | ★ 15.12% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $164,481,414.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.17 |
| 52 Week Low | $1.15 | $0.82 |
| 52 Week High | $12.46 | $1.88 |
Technical Indicators
Market Signals| Indicator | NERV | CLPS |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 45.93 |
| Support Level | $3.70 | $0.84 |
| Resistance Level | $4.07 | $0.89 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 62.37 | 17.66 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About CLPS CLPS Incorporation
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.